Specific chemotherapeutic agents such as decitabine have been observed to enhance the expression of tumor-associated antigens, including melanoma-associated antigen 3 (MAGE-A3), rendering ESCC cells more visible to the immune system. The gene discussed is MAGEA3; the disease is esophageal squamous cell carcinoma.